Vaccines - SAVIMS

COVID-19, Covid-19 vaccines, Peer-reviewed evidence, Resource Type, Vaccine effectiveness, Vaccines, Viral illnesses

Efficacy of NVX-CoV2373 Vaccine against B.1.351 Variant

Director | 05/05/2021 | COVID-19, Covid-19 vaccines, Peer-reviewed evidence, Resource Type, Vaccine effectiveness, Vaccines, Viral illnesses

Reference: Shinde, V., Bhikha, S., Hoosain, Z., Archary, M., Bhorat, Q., Fairlie, L., … & Madhi, S. A. (2021). Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant. The New England Journal of Medicine, 384(20), 1899-1909. https://doi.org/10.1056/NEJMoa2103055 Summary: The NVX-CoV2373 nanoparticle vaccine was evaluated in a phase 2 trial in South Africa during the B.1.351 […]

COVID-19, Covid-19 vaccines, Ethics, Genetic vaccines, Other scientific evidence, Reference Library, Resource Type, Vaccines, Viral illnesses

Merriam-Webster Updates Definition of “Vaccine”

Director | 30/04/2021 | COVID-19, Covid-19 vaccines, Ethics, Genetic vaccines, Other scientific evidence, Reference Library, Resource Type, Vaccines, Viral illnesses

Reference: Mair, V. (2021, April 30). Merriam-Webster gives “vaccine” a new definition. Language Log. Retrieved from https://languagelog.ldc.upenn.edu/nll/?p=50886 Summary: In a recent post, Victor Mair discusses an update to the definition of “vaccine” by Merriam-Webster. While traditional definitions describe vaccines as preparations of weakened or killed pathogens, the new entry expands this definition significantly. It now

COVID-19, Covid-19 vaccines, Epidemiological surveillance, Ethics, Other scientific evidence, Reference Library, Resource Type, Statistical evidence, Vaccine safety & adverse events, Vaccines, Viral illnesses

Monitoring the Effectiveness of the Ad26.COV2.S COVID-19 Vaccine in South African Healthcare Workers

Director | 29/04/2021 | COVID-19, Covid-19 vaccines, Epidemiological surveillance, Ethics, Other scientific evidence, Reference Library, Resource Type, Statistical evidence, Vaccine safety & adverse events, Vaccines, Viral illnesses

Reference: South African Medical Research Council. (2021). Sisonke Protocol Version 4.4 dated 29 Apr 2021. Summary: The Sisonke Protocol is an open-label, single-arm phase 3B study aimed at evaluating the effectiveness of the Ad26.COV2.S COVID-19 vaccine among healthcare workers in South Africa. This study involves approximately 500,000 healthcare workers aged 18 and older, who will

COVID-19, Covid-19 vaccines, Genetic vaccines, Peer-reviewed evidence, Resource Type, Vaccines, Viral illnesses

The Johnson & Johnson Vaccine for COVID-19

Director | 20/04/2021 | COVID-19, Covid-19 vaccines, Genetic vaccines, Peer-reviewed evidence, Resource Type, Vaccines, Viral illnesses

Reference: Livingston, E. H., Malani, P. N., & Creech, C. B. (2021). The Johnson & Johnson vaccine for COVID-19. JAMA Patient Page. https://doi.org/10.1001/jama.2021.2927 Summary: The Johnson & Johnson COVID-19 vaccine employs a unique approach using a modified adenovirus to induce an immune response without causing infection. Unlike mRNA vaccines from Pfizer and Moderna, which require

COVID-19, Covid-19 vaccines, Other scientific evidence, Resource Type, Vaccine safety & adverse events, Vaccines, Viral illnesses

Analysis of Adverse Drug Reactions for Covid-19 Vaccines

Director | 10/04/2021 | COVID-19, Covid-19 vaccines, Other scientific evidence, Resource Type, Vaccine safety & adverse events, Vaccines, Viral illnesses

Reference: VigiAccess. (2021). VigiAccess™. Retrieved from https://who-umc.org Summary: VigiAccess provides a comprehensive overview of adverse drug reactions (ADRs) associated with Covid-19 vaccines, highlighting a total of 2,183,912 reports. The data illustrates the geographical distribution of ADRs, with significant counts reported across continents such as the Americas, Europe, and Asia. The analysis categorises ADRs into various

COVID-19, Covid-19 vaccines, Peer-reviewed evidence, Resource Type, Treatment, Vaccine effectiveness, Vaccine safety & adverse events, Vaccines, Viral illnesses

Development of COVID-19 Vaccines Using Gene Therapy Technology

Director | 25/03/2021 | COVID-19, Covid-19 vaccines, Peer-reviewed evidence, Resource Type, Treatment, Vaccine effectiveness, Vaccine safety & adverse events, Vaccines, Viral illnesses

Reference: Nakagami, H. (2021). Development of COVID-19 vaccines utilizing gene therapy technology. International Immunology, 33(10), 521–527. https://doi.org/10.1093/intimm/dxab013 Summary: The article discusses the urgent development of COVID-19 vaccines in response to the SARS-CoV-2 outbreak. Various vaccine technologies are being explored, categorised into four main groups: intact target viruses, proteins, viral vectors, and nucleic acids. RNA and

COVID-19, Covid-19 vaccines, Peer-reviewed evidence, Resource Type, Vaccine effectiveness, Vaccine safety & adverse events, Vaccines, Viral illnesses

Unintended Consequences of mRNA Vaccines Against COVID-19

Director | 10/03/2021 | COVID-19, Covid-19 vaccines, Peer-reviewed evidence, Resource Type, Vaccine effectiveness, Vaccine safety & adverse events, Vaccines, Viral illnesses

Reference: Seneff, S., & Nigh, G. (2021). Worse than the disease? Reviewing some possible unintended consequences of the mRNA vaccines against COVID-19. International Journal of Vaccine Theory, Practice, and Research, 2(1), 38-58. Summary: The article by Seneff and Nigh reviews the mRNA vaccines developed for COVID-19, primarily focusing on the Pfizer and Moderna vaccines. While

COVID-19, Covid-19 vaccines, Other scientific evidence, Resource Type, Vaccine effectiveness, Vaccine safety & adverse events, Vaccines, Viral illnesses

Understanding mRNA COVID-19 Vaccines

Director | 04/03/2021 | COVID-19, Covid-19 vaccines, Other scientific evidence, Resource Type, Vaccine effectiveness, Vaccine safety & adverse events, Vaccines, Viral illnesses

Reference: Centres for Disease Control and Prevention. (2021, March 4). Understanding mRNA COVID-19 vaccines. https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines/mrna.html Summary: mRNA vaccines represent a novel approach to immunisation against infectious diseases, including COVID-19. They work by instructing cells to produce a harmless piece of the virus’s spike protein, eliciting an immune response without introducing the live virus. This process

COVID-19, Covid-19 vaccines, Other scientific evidence, Resource Type, Vaccine safety & adverse events, Vaccines, Viral illnesses

Efficacy and Safety of Janssen’s Ad26.COV2.S Vaccine for COVID-19

Director | 26/02/2021 | COVID-19, Covid-19 vaccines, Other scientific evidence, Resource Type, Vaccine safety & adverse events, Vaccines, Viral illnesses

Reference: FDA. (2021). Vaccines and related biological products advisory committee meeting: February 26, 2021. Janssen Ad26.COV2.S vaccine for the prevention of COVID-19. FDA Briefing Document. Summary: The FDA briefing document details the Emergency Use Authorization (EUA) request submitted by Janssen Biotech for the Ad26.COV2.S vaccine aimed at preventing COVID-19. This single-dose adenovirus vector vaccine demonstrated

COVID-19, Covid-19 vaccines, Ethics, Other scientific evidence, Reference Library, Resource Type, Vaccine safety & adverse events, Vaccines, Viral illnesses

Case Investigation Form for AEFI and AESI

Director | 28/01/2021 | COVID-19, Covid-19 vaccines, Ethics, Other scientific evidence, Reference Library, Resource Type, Vaccine safety & adverse events, Vaccines, Viral illnesses

Reference: Author. (2021). Case investigation form for AEFI serious, severe, cluster, AESI for all vaccines including COVID-19. Retrieved from [insert URL if available] Summary: The document is a Case Investigation Form designed to report Adverse Events Following Immunisation (AEFI) and Adverse Events of Special Interest (AESI) for all vaccines, including COVID-19. It is intended for